GovChime
Notice ID: df6c2375129a40959545546683d370c4Award NoticeAwarded

Olopatadine HCL 0.1% Ophthalmic Solution

Awarded on February 15, 2023. Full description on SAM.gov.

Awarded tounder SPE2D223D0007 (source: SAM.gov award notice)• $17.6M

Overview

Posted
September 24, 2026
Notice type
Award Notice
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of WarDEFENSE LOGISTICS AGENCY

Notice details

Office
TROOP SUPPORT MEDICAL.DLA TROOP SUPPORT
Place of performance
Ontario, Canada
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov
Award date
Feb 15, 2023
Award amount (SAM.gov award notice)
$17.6M

Identifiers

Solicitation number
SPE2D222R0117
Notice ID
df6c2375129a40959545546683d370c4
Award number (PIID)
SPE2D223D0007

Description

Modification SPE2D223D0007 P00013 No-Cost Settlement Termination for Convenience.

Modification SPE2D223D0007 P00012 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026).

Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle.

Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23.

Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027.

Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.

Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026. 

Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract. 

Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025. 

Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract. 

Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.     

Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.

Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle 

Full description on SAM.gov

Award Overview

Award Number

SPE2D223D0007

Award Amount (SAM.gov award notice)

$17.6M

Award Date

Feb 15, 2023

Awardee

Awardee UEI

GQLDJJ8AQNN5

Awardee CAGE Code

1HT23

Awardee Address

Camarillo, CA 93012, UNITED STATES

Line Item Number

0001

Original Solicitation

Notice ID: df6c2375129a40959545546683d370c4

Posted Date: Sep 24, 2026

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • SPE2D326F373X
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $147.36Signed Aug 12, 2026
  • SPE2D326F373Z
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $535.44Signed Aug 12, 2026
  • SPE2D326F375Z
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $27.3Signed Aug 12, 2026
  • SPE2D326F359Y
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $85.96Signed Aug 10, 2026
  • SPE2D326F357G
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $133.86Signed Aug 7, 2026

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

Files (14)

  • T4C Modification P00013 SPE2D223D0007 - Bilaterally Signed.pdf

    168 KBAdded in Award Notice version 9Posted
    Download
  • Modification P00012 SPE2D223D0007.PDF

    176 KBAdded in Award Notice version 9Posted
    Download
  • Signed Olopatadine HCL Oph Sol SPE2D223D0007 P00011 Mfg NDC Change.pdf

    237 KBAdded in Award Notice version 8Posted
    Download
  • Modification P00010 SPE2D223D0007.PDF

    171 KBAdded in Award Notice version 8Posted
    Download
  • Modification P00008 SPE2D223D0007 Option Year 3.PDF

    25 KBAdded in Award Notice version 7Posted
    Download
  • Modification P00007 SPE2D223D0007.PDF

    197 KBAdded in Award Notice version 7Posted
    Download
  • Option Year 2 Modification P00006 SPE2D223D0007.PDF

    25 KBAdded in Award Notice version 6Posted
    Download
  • Modification P00005 SPE2D223D0007.PDF

    188 KBAdded in Award Notice version 6Posted
    Download
  • Option Year 1 Modification P00004 SPE2D2-23-D-0007.PDF

    25 KBAdded in Award Notice version 5Posted
    Download
  • Signed SPE2D223D0007 P00003.pdf

    867 KBAdded in Award Notice version 4Posted
    Download
  • SF30_SPE2D223D0007P00002.PDF

    173 KBAdded in Award Notice version 4Posted
    Download
  • Signed Modification P00001 SPE2D2-23-D-0007.pdf

    109 KBAdded in Award Notice version 3Posted
    Download
  • Signed Award SPE2D2-23-D-0007 Olopatadine HCL 0.1% Ophthalmic Solution.pdf

    807 KBAdded in Award Notice version 2Posted
    Download
  • Olopatadine HCL 0.1% Ophthalmic Solution 5ML National Contract Solicitation SPE2D221R0117.pdf

    1.3 MBAdded in Solicitation version 2Posted
    Download

Lifecycle

  1. 1
    Version 1Solicitation

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice d8c76680a442496597cf8be46f36d57f on SAM.gov

  2. 2
    Version 2Award Notice

    Type changed from Solicitation to Award Notice

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice 8d5e0e51d3ce436b8321139419af067a on SAM.gov

  3. 3
    Version 3Award Notice

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice 66e5f5dd29d14fa587f524f225e52a4d on SAM.gov

  4. 4
    Version 4Award Notice

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice 7f7f49c42aee40d0b4353023bc02fc01 on SAM.gov

  5. 5
    Version 5Award Notice

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice de044b816b9742959497ad68baeb127a on SAM.gov

  6. 6
    Version 6Award Notice

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice 0d9911fb737e47f1a2aea39f9715757f on SAM.gov

  7. 7
    Version 7Award Notice

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice 172ef8534f7745e6b7958d9ad2800173 on SAM.gov

  8. 8
    Version 8Award Notice

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice bbf974a01ba842b69164b07632c5377e on SAM.gov

  9. 9
    Version 9Award NoticeCurrent

    Olopatadine HCL 0.1% Ophthalmic Solution

    Notice df6c2375129a40959545546683d370c4 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
The Defense Logistics Agency is issuing a solicitation for a national requirements contract for Epinephrine Injectors. Procurement details follow. Epinephrine 0.3 MG/0.3 ML Injection, Auto-Injector 2S in 2 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Jeremy Brown at (445) 737-5419, (jeremy.brown@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current solicitation date is October of 2026.
-Solicitation11/30/2026
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fentanyl Citrate Injection Solution. Procurement details follow. Fentanyl (PF) 50 MCG/ML Injection Solution in 1 ML, 2 ML, 5 ML,10 ML, 20 ML and 50 ML in Vials or Ampules, Pack Size of 1, 2, 5, 10, 20, and 50. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of War (DoW), Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Nancy Fernandez at (445) 737-0731 or Nancy.Fernandedz@dla.mil with any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is November/December of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date.
-Pre-SolicitationOpen
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil
-Market Research11/15/2026
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer.
-AwardedOpen
Please see attached for the sources sought notice/market research survey and MPID.
-Market Research11/30/2026

Additional Details

Solicitation Number

SPE2D222R0117

Archive Date

Feb 15, 2028

Place of Performance Country

CANADA

Office Address

PHILADELPHIA, PA, 19111